Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) – Pipeline Review, H2 2016’, provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics.

The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)

The report reviews Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects

The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Daiichi Sankyo Company, Limited

Intellipharmaceutics International Inc.

Mapi Pharma Ltd.

Pfizer Inc.

Prismic Pharmaceuticals, Inc.

Yuhan Corporation

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview 7

Therapeutics Development 8

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Stage of Development 8

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Therapy Area 9

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Indication 10

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Companies 13

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Companies Involved in Therapeutics Development 19

Daiichi Sankyo Company, Limited 19

Intellipharmaceutics International Inc. 20

Mapi Pharma Ltd. 21

Pfizer Inc. 22

Prismic Pharmaceuticals, Inc. 23

Yuhan Corporation 24

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Drug Profiles 25

(palmidrol + pregabalin) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

gabapentin - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

mirogabalin besylate - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

NVA-1309 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

pregabalin - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

pregabalin CR - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

pregabalin CR - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

pregabalin ER - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

pregabalin IR - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

pregabalin XR - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Dormant Projects 40

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Discontinued Products 41

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Featured News & Press Releases 42

Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules 42

Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain 42

Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica 42

Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate 43

Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia 43

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 43

Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 44

Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective 45

Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting 46

Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin 47

Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release) 47

Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China 48

Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case 49

Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion 49

Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin 50

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 19

Pipeline by Intellipharmaceutics International Inc., H2 2016 20

Pipeline by Mapi Pharma Ltd., H2 2016 21

Pipeline by Pfizer Inc., H2 2016 22

Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 23

Pipeline by Yuhan Corporation, H2 2016 24

Dormant Projects, H2 2016 40

Discontinued Products, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports